Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Meghali GoswamiGege GuiLaura W DillonKatherine E LindbladJulie ThompsonJanet ValdezDong-Yun KimJack Y GhannamKarolyn A OetjenChristin B DestefanoDana M SmithHanna TekleabYeusheng LiPradeep DagurThomas HughesJennifer L MartéJaydira Del RiveroJoanna Klubo-GwiezdzinksaJames L GulleyKatherine R CalvoCatherine LaiChristopher S HouriganPublished in: Journal for immunotherapy of cancer (2022)
Addition of pembrolizumab to 10-day decitabine therapy was clinically feasible in patients with R-AML, with immunological changes from PD-1 blockade observed in patients experiencing irAEs.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- ejection fraction
- advanced non small cell lung cancer
- newly diagnosed
- chronic kidney disease
- prognostic factors
- acute lymphoblastic leukemia
- diffuse large b cell lymphoma
- epidermal growth factor receptor
- replacement therapy